Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 14: 374-377, 1968;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Braverman, L. E.
Right arrow Articles by Pomfret, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braverman, L. E.
Right arrow Articles by Pomfret, D.

Clinical Chemistry, Vol 14, 374-377, Copyright © 1968 by the American Association for Clinical Chemistry

Formaldehyde-Forming Drugs and Urinary 17-Hydroxycorticosteroids

Lewis E. Braverman 1, Harold Reinstein 1, Humberto Loayza 1, and David Pomfret 1

1 Endocrine Division, St. Elizabeth’s Hospital, Brighton, Mass. 02135; and the Department of Medicine, Tufts University School of Medicine, and the Boston Medical Laboratory, Boston, Mass.

An apparent elevation of urinary 17-hydroxycorticosteroids may be found in the urine of patients receiving the formaldehyde-forming drug Mandelamine (methenamine mandelate), when the assay procedure depends on the formation of colored compounds with phenylhydrazine as determined at 1 wavelength (410 mµ). This false elevation may be eliminated by reading absorption at 3 wavelengths and using the Allen correction. However, the determination of 17-ketogenic steroids is not influenced by the presence of formaldehyde in the urine. Administration of Mandelamine or other formaldehyde-forming drugs should be stopped prior to the collection of urine in order to eliminate a potential source of error in determining 17-hydroxycorticosteroid excretion.

Submitted on June 26, 1967
Accepted on October 17, 1967






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1968 by the American Association for Clinical Chemistry.